Showing results (1-10 of 301) with videos related to
Sort By:
Pageof 31
Annals of Translational Medicine|May 14, 2021
Liver failure-future challenges and remaining questionsPeter Lemmer, Josef Christian Pospiech, Ali CanbayLiver International : Official Journal of the International Association for the Study of the Liver|September 27, 2023
Mechanisms and aetiology-dependent treatment of acute liver failurePeter Lemmer, Jan-Peter Sowa, Yesim Bulut, et al.Digestive Diseases (Basel, Switzerland)|March 25, 2024
Liver Stiffness Determined by Transient Elastography Is a Simple and Highly Accurate Predictor for Presence of Liver Cirrhosis in Clinical RoutinePeter Lemmer, Lydia Christina Rohr, Marie Henning, et al.Digestive Diseases (Basel, Switzerland)|September 1, 2021
Transaminase Concentrations Cannot Separate Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Irrespective of Histological AlgorithmPeter Lemmer, Nicole Selbach, Theodor Baars, et al.Zeitschrift Fur Gastroenterologie|January 9, 2023
Patients with NAFLD exhibit more advanced fibrosis in liver biopsy than patients with other chronic liver diseasesLydia Rohr, Peter Lemmer, Marie Henning, et al.Visceral Medicine|October 23, 2018
Intensive Care Therapy for Patients with Advanced Liver DiseasesAntonios Katsounas, Ali CanbayMedizinische Klinik (Munich, Germany : 1983)|June 29, 2006
[Specific therapy in acute liver failure]Ali Canbay, Guido GerkenCells|November 2, 2019
Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) ProgressionAline Gottlieb, Ali CanbayDigestive Diseases (Basel, Switzerland)|July 18, 2018
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver DiseaseRoger F Butterworth, Ali CanbayDrugs|February 2, 2019
L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver DiseaseAli Canbay, Jan-Peter SowaPageof 31